A Single Centre, Randomised, Double-blind, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2190915 in Healthy Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Fiboflapon (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 19 Oct 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 19 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.